CJC-1295 + GHRP-6 Stack vs IGF-1 LR3
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profileIGF-1 LR3
IGF-1 LR3 (Long Arg3 IGF-1) is a synthetic analogue of Insulin-like Growth Factor 1 with an amino acid substitution at position 3 and a 13-amino acid N-terminal extension. These modifications prevent binding to IGF-binding proteins (IGFBPs), dramatically extending its half-life from ~12 minutes (native IGF-1) to approximately 20–30 hours. IGF-1 LR3 is widely used in research for its ability to promote cellular growth, protein synthesis, hyperplasia, and nutrient uptake into muscle tissue.
Full profile| CJC-1295 + GHRP-6 Stack | IGF-1 LR3 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent) |
| Evidence | Research-stage | Research-stage |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol) |
| Administration | Subcutaneous injection | Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols) |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Hypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint pain |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols).
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); IGF-1 LR3 is Once daily post-workout, on training days only (common protocol).
- Research depth: this profile cites 2 sources for CJC-1295 + GHRP-6 Stack vs 3 for IGF-1 LR3.
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
IGF-1 LR3
In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.